Damora Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

DMRA$24.15+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended March 31,
	2026	2025
Operating expenses
Research and development	$23,777	$678
General and administrative	7,034	1,921
Total operating expenses	30,811	2,599
Loss from operations	(30,811)	(2,599)
Other income (expense), net
Interest income, net	3,070	74
Foreign exchange transaction gain (loss), net	—	(6)
Total other income, net	3,070	68
Loss before income tax expense	(27,741)	(2,531)
Income tax expense	(42)	(2)
Net loss	$(27,783)	$(2,533)
Net loss per share, basic and diluted, Series B Preferred Stock	$(353.72)	$—
Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted	16,366	—
Net loss per share, basic and diluted, Series C Preferred Stock	$(33.07)	$—
Weighted-average Series C non-voting convertible preferred stock outstanding, basic and diluted	20,079	—
Net loss per share, basic and diluted, common stock	$(0.62)	$(1.92)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	34,299,182	1,322,011
Other comprehensive (loss) income, net of tax
Currency translation (loss) gain	$(48)	$203
Other comprehensive (loss) income, net of tax	(48)	203
Total comprehensive loss	$(27,831)	$(2,330)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.